查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球数位生物製造市场：按技术类型、部署选项、製造的生物製品类型、主要地区划分——行业趋势和全球预测 (2023-2035)
市场调查报告书
商品编码
1264067

全球数位生物製造市场：按技术类型、部署选项、製造的生物製品类型、主要地区划分——行业趋势和全球预测 (2023-2035)

Digital Biomanufacturing Market - Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格

鑑于对生物製品的需求不断增长以及现有的挑战，利用数位技术帮助建立端到端连接流程以优化生物流程操作的解决方案。对生物製品的需求不断增加 如今，据说 20% 的组织已经采用数位化方法进行生物製造。

本报告考察了全球数位生物製造市场，提供了市场格局、技术竞争分析、公司概况、技术类型、部署选项、製造的生物製剂类型、按地区划分的市场预测，并提供了机会分析等信息。

内容

第一章前言

第 2 章执行摘要

第三章介绍

  • 章节概述
  • 医学数位生物製造概述
  • 支持数位生物製造的新技术
  • 与采用数位生物製造相关的挑战
  • 未来前景

第 4 章市场状况

  • 章节概述
  • PAT 提供商名单
  • DAS 供应商名单
  • MES 供应商名单
  • 数位孪生提供商名单

第五章技术竞争分析

  • 章节概述
  • 先决条件和关键参数
  • 调查方法
  • 技术竞争分析：PAT
  • 技术竞争分析：DAS
  • 技术竞争分析：MES
  • 技术竞争对手分析：数位孪生

第六章公司简介

  • 章节概述
  • 阿斯彭科技
  • FUJIFILM Diosynth Biotechnologies
  • 默克
  • 赛默飞世尔科技
  • Bioreactors.net
  • 赛多利斯
  • 达索系统
  • 通用电气医疗
  • 科伯

第七章基准分析

  • 章节概述
  • 调查方法和关键假设
  • 竞争基准：公司规模和地区
  • 竞争基准：创新和空白领域

第 8 章伙伴关係和协作

  • 章节概述
  • 合作模式
  • 数位製造：伙伴关係和协作清单

第九章市场集中度分析

  • 章节概述
  • 先决条件和关键参数
  • 调查方法
  • 市场集中度分析：顶级数位生物製造供应商

第 10 章工业生命週期分析

  • 章节概述
  • 工业生命週期分析
  • 数位生物製造：关键事件的时间表表现
  • 数位生物製造：创业活动
  • 数位生物製造：现有公司的活动
  • 数位生物製造：伙伴关係和协作的趋势
  • 数位生物製造：融资和投资趋势
  • 当前在生物製造中广泛采用数位化的障碍
  • 数位生物製造的未来前景
  • 工业生命週期分析：数位生物製造

第11章市场预测与机会分析

  • 章节概述
  • 预测调查方法和关键假设
  • 全球数位生物製造市场：2023-2035 年
  • 数位生物製造市场：按技术类型分析
  • 数位生物製造市场：按部署选项类型分析
  • 数位生物製造市场：按製造的生物製剂类型进行分析
  • 数位生物製造市场：区域分析

第十二章结束语

第13章访谈记录

  • 章节概述
  • BioIntelligence Technologies
  • Yokogawa Insilico Biotechnology
  • MasterControl
  • Trunovate
  • Dassault Systemes

第 14 章附录 I：表格数据

第 15 章附录 II：公司和组织名单

Product Code: RA100425

INTRODUCTION

Since the outbreak of COVID-19 infection, there has been immense pressure on the biopharmaceutical industry to reduce production timelines and increase the manufacturing capacity, without compromising on the quality of the final product. Further, a surge in morbidity across the globe and enhanced interconnectivity of equipment and technologies has led to an increased burden on manufacturing operations. Other factors that influenced the market include higher competition, competitive pricing, inflation rate, technological advancements and evolving regulatory guidelines. These factors demanded a fundamental shift from conventional manufacturing operations, which subsequently led to the introduction of industry 4.0 technologies. Digital biomanufacturing has emerged as a promising alternative to mitigate a number of bioprocessing related concerns, as well as significantly promote process robustness and product quality.

Digital biomanufacturing, popularly known as bioprocessing 4.0, refers to the integration of physical equipment with digital software and platforms, such as process analytical technologies (PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twins, in order to streamline the overall biomanufacturing process. Implementation of these technologies in monitoring, analytics and computing capabilities is expected to revolutionize current biomanufacturing practices. Further, digital bioprocessing is believed to have transformed manufacturing principles in areas, such as process development, operational activities, logistics and supply chain management, when used in combination with advanced technologies, including artificial intelligence (AI), machine learning and internet of things (IoT).

SCOPE OF THE REPORT

The Digital Biomanufacturing Market: Distribution by Type of Technology (PAT, DAS, MES and Digital Twins), Deployment Options (Cloud-based and On-premises), Type(s) of Biologic(s) Manufactured (Antibodies, Cell Therapies and Gene Therapies, Proteins, Vaccines, and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and the likely future potential of the digital biomanufacturing market, over the next 12 years. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key inclusions of the report are briefly discussed below:

Growing Demand for Biologics

Breakthroughs in the biotechnology industry, over the last few decades, has provided a considerable boost to the overall development landscape of biopharmaceutical drugs. In 2022, a milestone was witnessed when the number of approvals received by biologics narrowly outpaced those reported by small molecules. Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies. This can be attributed to the fact that the demand for biologics has been constantly increasing and is supported by continuous innovation in this field. Specifically, advancements in niche segments is expected to culminate in accelerated growth of the biologics market.

Need for Digital Biomanufacturing

According to a recent report, the development of a new drug takes 10-15 years, with an overall investment of USD 1-2 billion. Despite the significant investment of resources, over 90% of the candidates fail at different stages of clinical trials, resulting in huge financial losses for biomanufacturers.

As a direct consequence of the consistently growing demand for biologics and the existing challenges, there is an increase in the requirement for solutions that help in establishment of a digitally enabled and connected end-to-end process, in order to optimize bioprocess operations. Research suggests that, at present, 20% of the organizations have already adopted digitalized approaches for biomanufacturing. Such approaches are expected to enable an uninterrupted and accessible supply of cost-effective drugs that are likely to be launched commercially, with reduced development timelines. In fact, several leading biopharma players have claimed to achieve 40% increase in quality, 15% reduction in cost, 80% decrease in process variability and 20% shorter operational timelines by leveraging digital biomanufacturing advances. , , ,

Key Advantages of Digital Biomanufacturing

Currently, batch-to-batch variation and product validation are considered as major bottlenecks faced by the biologic industry. Digital biomanufacturing harnesses various advancements, such as real-time monitoring, data analytics, automation, modelling, process optimization and other digital tools to transform the available information into actionable insights. This is expected to help in the creation of a uniform process, which is capable of decreasing the deviation in quality of each batch. Other key benefits of digital biomanufacturing include improved efficiency, higher product yield, better product quality, data integrity, reduced manual intervention and limited risk of contamination. It is worth noting that digitalization in biopharmaceutical manufacturing is becoming an essential requirement, given its potential to develop enhanced quality products, with high speed, agility and sustainability.

Current Market Landscape of Digital Biomanufacturing

The digital biomanufacturing providers landscape features a mix of large, mid-sized and small companies, which have the required expertise and offer various digital services for the production of biologics. At present, more than 140 digital technologies have been / are being developed by over 100 industry stakeholders to enable the manufacturing of biologics. Further, various types of technologies currently facilitate smart biomanufacturing; of these, 48% are based on the principles of PAT, followed by those using MES (28%), DAS (14%) and digital twins (10%).

Key Trends in the Digital Biomanufacturing Market

Many stakeholders are undertaking initiatives to forge alliance with other industry / non-industry players. It is worth highlighting that over 75 strategic partnerships related to digital biomanufacturing have been inked since 2018, indicating that software providers are actively upgrading their technology related capabilities and accommodating the current and anticipated demand for digital biomanufacturing. Given the inclination towards cutting-edge technologies, along with innovative approaches to tailor the bioprocessing, we believe that the digital biomanufacturing technologies market is likely to evolve at a rapid pace, over the coming years. ,

Market Size of the Digital Biomanufacturing Market

Driven by improved data analytics, better product yield, faster production timelines, access to real time operations and rising interest in paperless manufacturing amongst innovators, lucrative opportunities are expected to emerge for players offering bioprocessing 4.0 services. The digital biomanufacturing market is anticipated to grow at a CAGR of 11%, during the period 2023-2035. In terms of type of technology, the digital biomanufacturing market for digital twins is expected to grow at a relatively faster pace (19%), till 2035. Further, currently, the market for on-premise deployment options is expected to capture the majority share, however, this trend is likely to change in the foreseen future with the rising popularity of cloud-based technologies.

Example Players in the Digital Biomanufacturing Market

Examples of players engaged in this domain include (which have also been captured in this report) AspenTech, Bioreactors.net, Dassault Systemes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Korber, Merck, Sartorius and Thermo Fisher Scientific.

The report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different regions. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research, offering a high-level view on the current state of the digital biomanufacturing market and its likely evolution in the mid-long term.
  • A general introduction to digital biomanufacturing, featuring a detailed discussion on various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing.
  • A detailed assessment of the overall market landscape of companies offering digital biomanufacturing technologies (PAT, DAS, MES and digital twins), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis).
  • A detailed competitiveness analysis of digital biomanufacturing technologies (PAT, DAS, MES and digital twins), based on supplier strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)) and type(s) of biologic(s) manufactured.
  • Elaborate profiles of key players (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing domain, which are actively providing software based on PAT, DAS, MES and digital twins. Each profile includes a brief overview of the company, along with information on capabilities of digital technologies offered by these firms, recent developments and an informed future outlook.
  • A benchmark analysis highlighting the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this domain, across key peer groups.
  • An analysis featuring information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.
  • A detailed analysis highlighting the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked.
  • A detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.

One of the key objectives of the report was to estimate the current opportunity and future growth potential of the digital biomanufacturing market. We have provided an informed estimate on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (PAT, DAS, MES and digital twins), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins, vaccines and others) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Joel Sirois (President and Chief Executive Officer, BioIntelligence Technologies)
  • Klaus Mauch (Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology)
  • Ciaran O'Keeffe (Director, Business Development and Channel Sales, MasterControl) and Isura Sirisena (Quality and Manufacturing Digitization Specialist, MasterControl)
  • Yaron Halfon (Director of Sales, Trunovate)
  • Barbara Holtz (Business Consultant, Dassault Systemes)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report was gathered via primary and secondary research. For all our projects, we conduct interviews / surveys with reputed domain experts (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What is the global market size of digital biomanufacturing?

Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.

Question 2: Which are the top players in the global digital biomanufacturing market?

Answer: Presently, more than 100 companies are engaged in digital biomanufacturing, worldwide. The top players engaged in this domain (which have also been captured in this report) include AspenTech, Bioreactors.net, Dassault Systemes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Korber, Merck, Sartorius and Thermo Fisher Scientific.

Question 3: What are the factors driving the digital biomanufacturing market?

Answer: Increasing number of approved biologics, growing number of biologics-related clinical trials, rise in R&D activity and a shift in preference for cloud-based processes, over the traditional biomanufacturing operations, has bolstered the demand for digital biomanufacturing software.

Question 4: Which region has the highest market share in the global digital biomanufacturing market?

Answer: North America and Europe capture around 75% share in the current global digital biomanufacturing market, followed by Asia-Pacific.

Question 5: What are the leading market segments in digital biomanufacturing market?

Answer: Currently, in terms of type of technology, process analytical technology captures the largest share (close to 50%) in the global digital biomanufacturing market. However, digital twins are likely to witness higher annual growth rates in the upcoming years, owing to their rising popularity. Further, in terms of type of company, software providers hold the largest share in the digital biomanufacturing market as compared to CDMOs.

Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?

Answer: At present, the global biomanufacturing market is dominated by the players providing on-premises deployment options, while the market is anticipated to shift towards the use of cloud-based technologies in the near future.

Question 7: What are the partnership and collaboration trends in the digital biomanufacturing domain?

Answer: At present, service alliances, technology utilization agreements and acquisitions are the most prominent types of partnerships inked between various stakeholders engaged in the digital biomanufacturing domain.

Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?

Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years.

CHAPTER OUTLINES

  • Chapter 1 is a preface providing an introduction to the full report, Digital Biomanufacturing Market, 2023-2035.
  • Chapter 2 is an executive summary of the insights captured during our research, offering a high-level view on the current state of the digital biomanufacturing market and its likely evolution in the mid-long term.
  • Chapter 3 provides a general introduction to digital biomanufacturing. It further includes a detailed discussion on the various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing.
  • Chapter 4 includes a detailed assessment of the overall market landscape of companies offering digital biomanufacturing technologies (PAT, DAS, MES, digital twins), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry).
  • Chapter 5 presents a detailed competitiveness analysis of digital biomanufacturing technologies (PAT, DAS, MES and digital twins) based on company strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)), and type(s) of biologic(s) manufactured.
  • Chapter 6 features elaborate profiles of key players (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing domain, which are actively providing software based on PAT, DAS, MES and digital twins. Each profile includes a brief overview of the company, along with information on the capabilities of digital technologies offered by these firms, recent developments and an informed future outlook.
  • Chapter 7 presents benchmark analysis of the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this domain, across key peer groups.
  • Chapter 8 features information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.
  • Chapter 9 highlights our opinion on the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked.
  • Chapter 10 presents a detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.
  • Chapter 11 presents a comprehensive market forecast analysis, highlighting the future potential of the market till 2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (PAT, DAS, MES and digital twins), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins vaccines, and others), and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).
  • Chapter 12 is a summary of the overall report. The chapter provides the key takeaways from the report, and presents facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the digital biomanufacturing market.
  • Chapter 13 is a collection of transcripts of interviews conducted with various stakeholders in the industry. We have presented details of interviews held Joel Sirois (President and Chief Executive Officer, BioIntelligence Technologies), Klaus Mauch (Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology), Ciaran O'Keeffe (Director, Business Development and Channel Sales, MasterControl), Isura Sirisena (Quality and Manufacturing Digitization Specialist, MasterControl), Yaron Halfon (Director of Sales, Trunovate) and Barbara Holtz (Business Consultant, Dassault Systemes).
  • Chapter 14 is an appendix, which contains tabulated data and numbers for all the figures included in this report.
  • Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Digital Biomanufacturing in Healthcare
  • 3.3. Emerging Technologies that Support Digital Biomanufacturing
    • 3.3.1. Process Analytical Technology (PAT)
    • 3.3.2. Data Analysis Software (DAS)
    • 3.3.3. Bioprocess Digital Twins
    • 3.3.4. Manufacturing Execution Systems (MES)
  • 3.4. Challenges Associated with the Adoption of Digital Biomanufacturing
  • 3.5. Future Perspectives

4. MARKERT LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. List of Process Analytical Technology (PAT) Providers
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters (Region-wise)
    • 4.2.4. Analysis by Location of Headquarters (Country-wise)
    • 4.2.5. Analysis by Type of Company
    • 4.2.6. Analysis by Number of Platforms Offered
    • 4.2.7. Analysis by Deployment Options
    • 4.2.8. Analysis by Platform Capabilities
    • 4.2.9. Analysis by Type(s) of Biologic(s) Manufactured
    • 4.2.10. Analysis by Other Compatible Platforms
    • 4.2.11. Analysis by Type of End User(s)
    • 4.2.12. Analysis by Year of Establishment, Location of Headquarters and Platform Capabilities
    • 4.2.13. Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
  • 4.3. List of Data Analysis Software (DAS) Providers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters (Region-wise)
    • 4.3.4. Analysis by Location of Headquarters (Country-wise)
    • 4.3.5. Analysis by Type of Company
    • 4.3.6. Analysis by Number of Software Offered
    • 4.3.7. Analysis by Deployment Options
    • 4.3.8. Analysis by Software Capabilities
    • 4.3.9. Analysis by Other Compatible Platforms
    • 4.3.10. Analysis by Type of End User(s)
    • 4.3.11. Analysis by Year of Establishment, Location of Headquarters and Software Capabilities
    • 4.3.12. Analysis by Years of Experience, Location of Headquarters and Number of Software Capabilities (Dot-Plot Representation)
  • 4.4. List of Manufacturing Execution Systems (MES) Providers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size
    • 4.4.3. Analysis by Location of Headquarters (Region-wise)
    • 4.4.4. Analysis by Location of Headquarters (Country-wise)
    • 4.4.5. Analysis by Type of Company
    • 4.4.6. Analysis by Number of Platforms Offered
    • 4.4.7. Analysis by Deployment Options
    • 4.4.8. Analysis by Platform Capabilities
    • 4.4.9. Analysis by Integrating Software
    • 4.4.10. Analysis by Type of Service(s) Offered
    • 4.4.11. Analysis by Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
  • 4.5. List of Digital Twins Providers
    • 4.5.1. Analysis by Year of Establishment
    • 4.5.2. Analysis by Company Size
    • 4.5.3. Analysis by Location of Headquarters (Region-wise)
    • 4.5.4. Analysis by Location of Headquarters (Country-wise)
    • 4.5.5. Analysis by Number of Platforms Offered
    • 4.5.6. Analysis by Area(s) of Application
    • 4.5.7. Analysis by Type of End User(s)
    • 4.5.8. Analysis by Years of Experience, Location of Headquarters and Area(s) of Application (Dot-Plot Representation)

5. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Parameters
  • 5.3. Methodology
  • 5.4. Technology Competitiveness Analysis: Process Analytical Technologies
    • 5.4.1. Process Analytical Technologies Offered by Small Companies
    • 5.4.2. Process Analytical Technologies Offered by Mid-sized Companies
    • 5.4.3. Process Analytical Technologies Offered by Large Companies
    • 5.4.4. Process Analytical Technologies Offered by Very Large Companies
  • 5.5. Technology Competitiveness Analysis: Data Analysis Software
  • 5.6. Technology Competitiveness Analysis: Manufacturing Execution Systems
    • 5.6.1. Manufacturing Execution Systems Offered by Small Companies
    • 5.6.2. Manufacturing Execution Systems Offered by Mid-sized Companies
    • 5.6.3. Manufacturing Execution Systems Offered by Large and Very Large Companies
  • 5.7. Technology Competitiveness Analysis: Digital Twins

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. AspenTech
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Technology Portfolio
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. FUJIFILM Diosynth Biotechnologies
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Technology Portfolio
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. Merck
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Technology Portfolio
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Thermo Fisher Scientific
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3.
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Bioreactors.net
    • 6.6.1. Company Overview
    • 6.6.2. Technology Portfolio
    • 6.6.3. Recent Developments and Future Outlook
  • 6.7. Sartorius
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Technology Portfolio
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. Dassault Systemes
    • 6.8.1. Company Overview
    • 6.8.2. Financial Information
    • 6.8.3. Area(s) of Application
    • 6.8.4. Recent Developments and Future Outlook
  • 6.9. GE Healthcare
    • 6.9.1. Company Overview
    • 6.9.2. Technology Portfolio
    • 6.9.3. Recent Developments and Future Outlook
  • 6.10. Korber
    • 6.10.1. Company Overview
    • 6.10.2. Financial Information
    • 6.10.3. Technology Portfolio
    • 6.10.4. Recent Developments and Future Outlook

7. BENCHMARKING ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Methodology and Key Assumptions
  • 7.3. Competitive Benchmarking by Company Size and Region
    • 7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
    • 7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
    • 7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
    • 7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
    • 7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
    • 7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
    • 7.3.7. Competitive Benchmarking: Small, Mid-sized and Very Large Players based in Asia-Pacific (Peer Group VII)
  • 7.4. Competitive Benchmarking: Pockets of Innovation and White Spaces

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Digital Biomanufacturing: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Analysis by Type of Technology
    • 8.3.5. Analysis by Year of Partnership and Type of Technology
    • 8.3.6. Most Active Players: Analysis by Number of Partnerships
    • 8.3.7. Analysis by Geography
      • 8.3.7.1. Intracontinental and Intercontinental Agreements
      • 8.3.7.2. International and Local Agreements

9. MARKET CONCENTRATION ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
  • 9.4. Market Concertation Analysis: Top Digital Biomanufacturing Providers

10. INDUSTRY LIFECYCLE ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Industry Lifecycle Analysis
  • 10.3. Digital Biomanufacturing: Historical Timeline of Key Events
  • 10.4. Digital Biomanufacturing: Start-up Activity
  • 10.5. Digital Biomanufacturing: Established Players Activity
  • 10.6. Digital Biomanufacturing: Partnership and Collaboration Trends
  • 10.7. Digital Biomanufacturing: Funding and Investments Trends
  • 10.8. Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
  • 10.9. Future Outlook of Digital Biomanufacturing
  • 10.10. Industry Lifecycle Analysis: Digital Biomanufacturing

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Global Digital Biomanufacturing Market, 2023-2035
  • 11.4. Digital Biomanufacturing Market: Analysis by Type of Technology
    • 11.4.1. Digital Biomanufacturing Market for PAT, 2023-2035
    • 11.4.2. Digital Biomanufacturing Market for DAS, 2023-2035
    • 11.4.3. Digital Biomanufacturing Market for MES, 2023-2035
    • 11.4.4. Digital Biomanufacturing Market for Digital Twins, 2023-2035
  • 11.5. Digital Biomanufacturing Market: Analysis by Type of Deployment Options
    • 11.5.1. Digital Biomanufacturing Market for Cloud-based Deployment Options, 2023- 2035
    • 11.5.2. Digital Biomanufacturing Market for On-premises Deployment Options, 2023- 2035
  • 11.6. Digital Biomanufacturing Market: Analysis by Type(s) of Biologic(s) Manufactured
    • 11.6.1. Digital Biomanufacturing Market for Antibodies, 2023-2035
    • 11.6.2. Digital Biomanufacturing Market for Cell and Gene Therapies, 2023-2035
    • 11.6.3. Digital Biomanufacturing Market for Proteins, 2023-2035
    • 11.6.4. Digital Biomanufacturing Market for Vaccines, 2023-2035
    • 11.6.5. Digital Biomanufacturing Market for Others, 2023-2035
  • 11.7. Digital Biomanufacturing Market: Analysis by Geography
    • 11.7.1. Digital Biomanufacturing Market in North America, 2023-2035
    • 11.7.2. Digital Biomanufacturing Market in Europe, 2023-2035
    • 11.7.3. Digital Biomanufacturing Market in Asia-Pacific, 2023-2035
    • 11.7.4. Digital Biomanufacturing Market in Latin America, 2023-2035
    • 11.7.5. Digital Biomanufacturing Market in Middle East and North Africa, 2023-2035

12. CONCLUDING REMARKS

13. INTERVIEW TRANSCRIPTS

  • 13.1. Chapter Overview
  • 13.2. BioIntelligence Technologies
    • 13.2.1. Interview Transcript: Joel Sirois, Chief Executive Officer and President
  • 13.2. Yokogawa Insilico Biotechnology
    • 13.2.1. Interview Transcript: Klaus Mauch, Managing Director and Chief Executive Officer
  • 13.3. MasterControl
    • 13.3.1. Interview Transcript: Ciaran O'Keeffe, Director, Business Development and Channel Sales, and Isura Sirisena, Quality and Manufacturing Digitization Specialist
  • 13.4. Trunovate
    • 13.4.1. Interview Transcript: Yaron Halfon, Director of Sales
  • 13.5. Dassault Systemes
    • 13.5.1. Interview Transcript: Barbara Holtz, Business Consultant

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 4.1 List of Process Analytical Technology Providers
  • Table 4.2 Process Analytical Technology Providers: Information on Platform and Deployment Options
  • Table 4.3 Process Analytical Technologies: Information on Platform Capabilities
  • Table 4.4 Process Analytical Technologies: Information on Type(s) of Biologic(s) Manufactured, Other Compatible Platforms and Type of End User(s)
  • Table 4.5 List of Data Analysis Software Providers
  • Table 4.6 Data Analysis Software Providers: Information on Deployment Options
  • Table 4.7 Data Analysis Software: Information on Software Capabilities
  • Table 4.8 Data Analysis Software: Information on Type of Biologic(s) Manufactured, Other Compatible Platforms and Type of End User(s)
  • Table 4.9 List of Manufacturing Execution Systems Providers
  • Table 4.10 Manufacturing Execution Systems Providers: Information on Deployment Options
  • Table 4.11 Manufacturing Execution Systems: Information on Platform Capabilities
  • Table 4.12 Manufacturing Execution Systems: Information on Area(s) of Application and Type of End User(s)
  • Table 4.13 List of Digital Twins Providers
  • Table 4.14 Digital Twins Technologies: Information on Area(s) of Application and Type of End User(s)
  • Table 5.1 Technology Competitiveness Analysis: Information on Peer Groups
  • Table 6.1 List of Companies Profiled
  • Table 6.2 AspenTech: Company Snapshot
  • Table 6.3 AspenTech: Recent Developments and Future Outlook
  • Table 6.4 FUJIFILM Diosynth Biotechnologies: Company Snapshot
  • Table 6.5 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
  • Table 6.6 Merck: Company Snapshot
  • Table 6.7 Merck: Recent Developments and Future Outlook
  • Table 6.8 Thermo Fisher Scientific: Company Snapshot
  • Table 6.9 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 6.10 Bioreactors.net: Company Snapshot
  • Table 6.11 Sartorius: Company Snapshot
  • Table 6.12 Sartorius: Recent Developments and Future Outlook
  • Table 6.13 Dassault Systemes: Company Snapshot
  • Table 6.14 GE Healthcare: Company Snapshot
  • Table 6.15 GE Healthcare: Recent Developments and Future Outlook
  • Table 6.16 Korber: Company Snapshot
  • Table 6.17 Korber: Recent Developments and Future Outlook
  • Table 7.1 Benchmark Analysis: Information on Peer Groups
  • Table 8.1 Digital Biomanufacturing: List of Partnerships and Collaborations, 2018-2022
  • Table 8.2 Digital Biomanufacturing: Information on Type of Agreement (Country-wise and Continent-wise), 2018-2022
  • Table 9.1 Market Concertation Analysis: Information on Years of Entrance and Key Offerings of Top Digital Biomanufacturing Providers
  • Table 10.1 Industry Lifecycle Analysis
  • Table 10.2 Industry Lifecycle Analysis: Digital Biomanufacturing
  • Table 13.1 BioIntelligence Technologies: Company Snapshot
  • Table 13.2 Yokogawa Insilico Biotechnology: Company Snapshot
  • Table 13.3 MasterControl: Company Snapshot
  • Table 13.4 Trunovate: Company Snapshot
  • Table 13.5 Dassault Systemes: Company Snapshot
  • Table 14.1 Digital Biomanufacturing Providers: Distribution by Type of Technology
  • Table 14.2 Process Analytical Technology Providers: Distribution by Year of Establishment
  • Table 14.3 Process Analytical Technology Providers: Distribution by Company Size
  • Table 14.4 Process Analytical Technology Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 14.5 Process Analytical Technology Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 14.6 Process Analytical Technology Providers: Distribution by Type of Company
  • Table 14.7 Process Analytical Technology Providers: Distribution by Number of Platforms Offered
  • Table 14.8 Process Analytical Technology Provider: Distribution by Deployment Options
  • Table 14.9 Process Analytical Technologies: Distribution by Platform Capabilities
  • Table 14.10 Process Analytical Technologies: Distribution by Type(s) of Biologic(s) Manufactured
  • Table 14.11 Process Analytical Technologies: Distribution by Other Compatible Platforms
  • Table 14.12 Process Analytical Technology Providers: Distribution by Type of End User(s)
  • Table 14.13 Process Analytical Technologies: Distribution by Year of Establishment, Location of Headquarters and Platform Capabilities
  • Table 14.14 Data Analysis Software Providers: Distribution by Year of Establishment
  • Table 14.15 Data Analysis Software Providers: Distribution by Company Size
  • Table 14.16 Data Analysis Software Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 14.17 Data Analysis Software Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 14.18 Data Analysis Software Providers: Distribution by Type of Company
  • Table 14.19 Data Analysis Software Providers: Distribution by Number of Software Offered
  • Table 14.20 Data Analysis Software Providers: Distribution by Deployment Options
  • Table 14.21 Data Analysis Software: Distribution by Software Capabilities
  • Table 14.22 Data Analysis Software: Distribution by Other Compatible Platforms
  • Table 14.23 Data Analysis Providers: Distribution by Type of End User(s)
  • Table 14.24 Data Analysis Software: Distribution by Year of Establishment, Location of Headquarters and Software Capabilities
  • Table 14.25 Manufacturing Execution Systems Providers: Distribution by Year of Establishment
  • Table 14.26 Manufacturing Execution Systems Providers: Distribution by Company Size
  • Table 14.27 Manufacturing Execution Systems Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 14.28 Manufacturing Execution Systems Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 14.29 Manufacturing Execution Systems Providers: Distribution by Type of Company
  • Table 14.30 Manufacturing Execution Systems Providers: Distribution by Number of Platforms Offered
  • Table 14.31 Manufacturing Execution Systems Providers: Distribution by Deployment Options
  • Table 14.32 Manufacturing Execution Systems: Distribution by Platform Capabilities
  • Table 14.33 Manufacturing Execution Systems: Distribution by Integrating Software
  • Table 14.34 Manufacturing Execution Systems: Distribution by Types of Service(s) Offered
  • Table 14.35 Digital Twins Providers: Distribution by Year of Establishment
  • Table 14.36 Digital Twins Providers: Distribution by Company Size
  • Table 14.37 Digital Twins Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 14.38 Digital Twins Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 14.39 Digital Twins Providers: Distribution by Number of Platforms Offered
  • Table 14.40 Digital Twins Technologies: Distribution by Area(s) of Application
  • Table 14.41 Digital Twins Providers: Distribution by Type of End User(s)
  • Table 14.42 AspenTech: Annual Revenues, FY 2020-3M 2023 (USD Million)
  • Table 14.43 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-H1 2022 (USD Million)
  • Table 14.44 Merck: Annual Revenues, FY 2018-9M 2022 (USD Billion)
  • Table 14.45 Thermo Fisher Scientific: Annual Revenues, FY 2017-FY 2022 (USD Billion)
  • Table 14.46 Sartorius: Annual Revenues, FY 2017-FY 2022 (USD Million)
  • Table 14.47 Dassault Systemes: Annual Revenues, FY 2017-FY 2021 (USD Billion)
  • Table 14.48 Korber: Annual Revenues, FY 2019-FY 2021 (USD Million)
  • Table 14.49 Benchmark Analysis: Distribution by Company Size and Region
  • Table 14.50 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 14.51 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.52 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 14.53 Partnerships and Collaborations: Distribution by Type of Technology
  • Table 14.54 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Technology
  • Table 14.55 Most Active Players: Distribution by Number of Partnerships
  • Table 14.56 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Table 14.57 Partnerships and Collaborations: International and Local Agreements
  • Table 14.58 Digital Biomanufacturing: Start-up Activity
  • Table 14.59 Global Digital Biomanufacturing Market, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.60 Digital Biomanufacturing Market: Distribution by Type of Technology, 2023 and 2035
  • Table 14.61 Digital Biomanufacturing Market for PAT, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.62 Digital Biomanufacturing Market for DAS, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.63 Digital Biomanufacturing Market for MES, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.64 Digital Biomanufacturing Market for Digital Twins, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.65 Digital Biomanufacturing Market: Distribution by Type of Deployment Options, 2023 and 2035
  • Table 14.66 Digital Biomanufacturing Market for Cloud-based Deployment Options, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.67 Digital Biomanufacturing Market for On-premises Deployment Options, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.68 Digital Biomanufacturing Market: Distribution by Type(s) of Biologic(s) Manufactured, 2023 and 2035
  • Table 14.69 Digital Biomanufacturing Market for Antibodies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.70 Digital Biomanufacturing Market for Cell and Gene Therapies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.71 Digital Biomanufacturing Market for Proteins, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.72 Digital Biomanufacturing Market for Vaccines, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.73 Digital Biomanufacturing Market for Others, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.74 Digital Biomanufacturing Market: Distribution by Geography, 2023 and 2035
  • Table 14.75 Digital Biomanufacturing Market in North America, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.76 Digital Biomanufacturing Market in Europe, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.77 Digital Biomanufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.78 Digital Biomanufacturing Market in Latin America, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
  • Table 14.79 Digital Biomanufacturing Market in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Market Landscape
  • Figure 2.2 Executive Summary: Partnerships and Collaborations
  • Figure 2.3 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Overview of Digital Biomanufacturing in Healthcare
  • Figure 3.2 Software Capabilities in Digital Biomanufacturing
  • Figure 3.3 Challenges Associated with the Adoption of Digital Biomanufacturing
  • Figure 4.1 Digital Biomanufacturing Providers: Distribution by Type of Technology
  • Figure 4.2 Process Analytical Technology Providers: Distribution by Year of Establishment
  • Figure 4.3 Process Analytical Technology Providers: Distribution by Company Size
  • Figure 4.4 Process Analytical Technology Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.5 Process Analytical Technology Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.6 Process Analytical Technology Providers: Distribution by Type of Company
  • Figure 4.7 Process Analytical Technology Providers: Distribution by Number of Platforms Offered
  • Figure 4.8 Process Analytical Technology Provider: Distribution by Deployment Options
  • Figure 4.9 Process Analytical Technologies: Distribution by Platform Capabilities
  • Figure 4.10 Process Analytical Technologies: Distribution by Type(s) of Biologic(s) Manufactured
  • Figure 4.11 Process Analytical Technologies: Distribution by Other Compatible Platforms
  • Figure 4.12 Process Analytical Technology Providers: Distribution by Type of End User(s)
  • Figure 4.13 Process Analytical Technologies: Distribution by Year of Establishment, Location of Headquarters and Platform Capabilities
  • Figure 4.14 Process Analytical Technologies offered by Small Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
  • Figure 4.15 Process Analytical Technologies offered by Mid-sized Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
  • Figure 4.16 Process Analytical Technologies offered by Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
  • Figure 4.17 Process Analytical Technologies offered by Very Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
  • Figure 4.18 Data Analysis Software Providers: Distribution by Year of Establishment
  • Figure 4.19 Data Analysis Software Providers: Distribution by Company Size
  • Figure 4.20 Data Analysis Software Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.21 Data Analysis Software Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.22 Data Analysis Software Providers: Distribution by Type of Company
  • Figure 4.23 Data Analysis Software Providers: Distribution by Number of Software Offered
  • Figure 4.24 Data Analysis Software Provider: Distribution by Deployment Options
  • Figure 4.25 Data Analysis Software: Distribution by Software Capabilities
  • Figure 4.26 Data Analysis Software: Distribution by Other Compatible Platforms
  • Figure 4.27 Data Analysis Providers: Distribution by Type of End User(s)
  • Figure 4.28 Data Analysis Software: Distribution by Year of Establishment, Location of Headquarters and Software Capabilities
  • Figure 4.29 Data Analysis Software Providers: Distribution by Years of Experience, Location of Headquarters and Number of Software Capabilities
  • Figure 4.30 Manufacturing Execution Systems Providers: Distribution by Year of Establishment
  • Figure 4.31 Manufacturing Execution Systems Providers: Distribution by Company Size
  • Figure 4.32 Manufacturing Execution Systems Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.33 Manufacturing Execution Systems Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.34 Manufacturing Execution Systems Providers: Distribution by Type of Company
  • Figure 4.35 Manufacturing Execution Systems Providers: Distribution by Number of Platforms Offered
  • Figure 4.36 Manufacturing Execution Systems Providers: Distribution by Deployment Options
  • Figure 4.37 Manufacturing Execution Systems: Distribution by Platform Capabilities
  • Figure 4.38 Manufacturing Execution Systems: Distribution by Integrating Software
  • Figure 4.39 Manufacturing Execution Systems: Distribution by Types of Service(s) Offered
  • Figure 4.40 Manufacturing Execution Systems Offered by Small Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
  • Figure 4.41 Manufacturing Execution Systems Offered by Mid-sized Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
  • Figure 4.42 Manufacturing Execution Systems offered by Large and Very Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
  • Figure 4.43 Digital Twins Providers: Distribution by Year of Establishment
  • Figure 4.44 Digital Twins Providers: Distribution by Company Size
  • Figure 4.45 Digital Twins Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.46 Digital Twins Providers: Distribution by Location of Headquarters (Country- wise)
  • Figure 4.47 Digital Twins Providers: Distribution by Number of Platforms Offered
  • Figure 4.48 Digital Twins Technologies: Distribution by Area(s) of Application
  • Figure 4.49 Digital Twins Providers: Distribution by Type of End User(s)
  • Figure 4.50 Digital Twins Providers: Distribution by Years of Experience, Location of Headquarters and Area(s) of Application
  • Figure 5.1 Process Analytical Technologies Offered by Small Companies
  • Figure 5.2 Process Analytical Technologies Offered by Mid-sized Companies
  • Figure 5.3 Process Analytical Technologies Offered by Large Companies
  • Figure 5.4 Process Analytical Technologies Offered by Very Large Companies
  • Figure 5.5 Technology Competitiveness Analysis: Data Analysis Software
  • Figure 5.6 Manufacturing Execution Systems Offered by Small Companies
  • Figure 5.7 Manufacturing Execution Systems Offered by Mid-sized Companies
  • Figure 5.8 Manufacturing Execution Systems Offered by Large and Very Large Companies
  • Figure 5.9 Technology Competitiveness Analysis: Digital Twins Technologies
  • Figure 6.1 AspenTech: Annual Revenues, FY 2020-3M 2023 (USD Million)
  • Figure 6.2 AspenTech: Technology Capabilities
  • Figure 6.3 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-H1 2022 (USD Million)
  • Figure 6.4 FUJIFILM Diosynth Biotechnologies: Technology Capabilities
  • Figure 6.5 Merck: Annual Revenues, FY 2018-9M 2022 (USD Billion)
  • Figure 6.6 Merck: Technology Capabilities
  • Figure 6.7 Thermo Fisher Scientific: Annual Revenues, FY 2017-FY 2022 (USD Billion)
  • Figure 6.8 Thermo Fisher Scientific: Technology Capabilities
  • Figure 6.9 Bioreactors.net: Technology Capabilities
  • Figure 6.10 Sartorius: Annual Revenues, FY 2017-FY 2022 (USD Million)
  • Figure 6.11 Sartorius: Technology Capabilities
  • Figure 6.12 Dassault Systemes: Annual Revenues, FY 2017-FY 2021 (USD Billion)
  • Figure 6.13 Dassault Systemes: Area(s) of Application(s)
  • Figure 6.14 GE Healthcare: Technology Capabilities
  • Figure 6.15 Korber: Annual Revenues, FY 2019-FY 2021 (USD Million)
  • Figure 6.16 Korber: Technology Capabilities
  • Figure 7.1 Benchmark Analysis: Distribution by Company Size and Region
  • Figure 7.2 Competitive Benchmarking: Small Players based in North America

(Peer Group I)

  • Figure 7.3 Competitive Benchmarking: Mid-sized Players based in North America

(Peer Group II)

  • Figure 7.4 Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
  • Figure 7.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
  • Figure 7.6 Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
  • Figure 7.7 Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
  • Figure 7.8 Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific (Peer Group VII)
  • Figure 7.9 White Spaces: Distribution of Peer Groups by Type of Technology and Type of Company
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Technology
  • Figure 8.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Technology
  • Figure 8.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.7 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 8.8 Partnerships and Collaborations: International and Local Agreements
  • Figure 9.1 Market Concertation Analysis: Comparison of Key Offerings of Top Digital Biomanufacturing Providers
  • Figure 10.1 Digital Biomanufacturing: Historical Timeline of Key Events
  • Figure 10.2 Digital Biomanufacturing: Start-up Activity
  • Figure 10.3 Digital Biomanufacturing: Established Players Activity
  • Figure 10.4 Digital Biomanufacturing: Partnership and Collaboration Trends
  • Figure 10.5 Digital Biomanufacturing: Funding and Investments Trends
  • Figure 10.6 Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
  • Figure 10.7 Future Outlook of Digital Biomanufacturing
  • Figure 10.8 Industry Lifecycle Analysis: Digital Biomanufacturing
  • Figure 11.1 Global Digital Biomanufacturing Market, 2023-2035 (USD Million)
  • Figure 11.2 Digital Biomanufacturing Market: Distribution by Type of Technology, 2023

and 2035

  • Figure 11.3 Digital Biomanufacturing Market for PAT, 2023-2035 (USD

Million)

  • Figure 11.4 Digital Biomanufacturing Market for DAS, 2023-2035 (USD Million)
  • Figure 11.5 Digital Biomanufacturing Market for MES, 2023-2035 (USD Million)
  • Figure 11.6 Digital Biomanufacturing Market for Digital Twins, 2023-2035 (USD Million)
  • Figure 11.7 Digital Biomanufacturing Market: Distribution by Type of Deployment Options, 2023 and 2035
  • Figure 11.8 Digital Biomanufacturing Market for Cloud-based Deployment Options, 2023- 2035 (USD Million)
  • Figure 11.9 Digital Biomanufacturing Market for On-premises Deployment Options, 2023- 2035 (USD Million)
  • Figure 11.10 Digital Biomanufacturing Market: Distribution by Type(s) of Biologic(s) Manufactured, 2023 and 2035
  • Figure 11.11 Digital Biomanufacturing Market for Antibodies, 2023-2035 (USD Million)
  • Figure 11.12 Digital Biomanufacturing Market for Cell and Gene Therapies, 2023-2035 (USD

Million)

  • Figure 11.13 Digital Biomanufacturing Market for Proteins, 2023-2035 (USD Million)
  • Figure 11.14 Digital Biomanufacturing Market for Vaccines, 2023-2035 (USD Million)
  • Figure 11.15 Digital Biomanufacturing Market for Others, 2023-2035 (USD Million)
  • Figure 11.16 Digital Biomanufacturing Market: Distribution by Geography, 2023 and 2035
  • Figure 11.17 Digital Biomanufacturing Market in North America, 2023-2035 (USD Million)
  • Figure 11.18 Digital Biomanufacturing Market in Europe, 2023-2035 (USD Million)
  • Figure 11.19 Digital Biomanufacturing Market in Asia-Pacific, 2023-2035 (USD Million)
  • Figure 11.20 Digital Biomanufacturing Market in Latin America, 2023-2035 (USD Million)
  • Figure 11.21 Digital Biomanufacturing Market in Middle East and North Africa, 2023-2035

(USD Million)

  • Figure 12.1 Concluding Remarks: Overall Market Landscape
  • Figure 12.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 12.3 Concluding Remarks: Market Forecast and Opportunity Analysis